SELEURL PHARMACIE DE SAALES : revenue, balance sheet and financial ratios

SELEURL PHARMACIE DE SAALES is a French company founded 10 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAALES (67420), this company of category PME shows in 2017 a revenue of 980 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELEURL PHARMACIE DE SAALES (SIREN 814178356)
Indicator 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C N/C 980 307 € 1 111 287 €
Net income 33 380 € 5 364 € -15 056 € 255 421 € 33 812 € 71 461 € 80 088 € 84 790 €
EBITDA N/C N/C N/C N/C N/C N/C 124 379 € 134 689 €
Net margin N/C N/C N/C N/C N/C N/C 8.2% 7.6%

Revenue and income statement

In 2023, SELEURL PHARMACIE DE SAALES generates positive net income of 33 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2023: 85 k€ -> 33 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

33 380 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 22%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 78%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

22.3%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

77.655%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

65.1%

Solvency indicators evolution
SELEURL PHARMACIE DE SAALES

Sector positioning

Debt ratio
22.3 2023
2021
2022
2023
Q1: 20.09
Med: 66.92
Q3: 169.22
Good -28 pts over 3 years

In 2023, the debt ratio of SELEURL PHARMACIE DE SAALES (22.30) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
77.66% 2023
2021
2022
2023
Q1: 28.71%
Med: 48.51%
Q3: 68.18%
Excellent +28 pts over 3 years

In 2023, the financial autonomy of SELEURL PHARMACIE DE SAALES (77.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 1625.06. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

1625.064

Liquidity indicators evolution
SELEURL PHARMACIE DE SAALES

Sector positioning

Liquidity ratio
1625.06 2023
2021
2022
2023
Q1: 135.26
Med: 189.75
Q3: 270.27
Excellent +12 pts over 3 years

In 2023, the liquidity ratio of SELEURL PHARMACIE DE SAALES (1625.06) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELEURL PHARMACIE DE SAALES

Positioning of SELEURL PHARMACIE DE SAALES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2023, the value of SELEURL PHARMACIE DE SAALES is estimated at 393 866 € (range 239 529€ - 553 687€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
220 transactions
239k€ 393k€ 553k€
393 866 € Range: 239 529€ - 553 687€
NAF 5 année 2023

Valuation method used

Net Income Multiple
33 380 € × 11.8x = 393 867 €
Range: 239 529€ - 553 688€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELEURL PHARMACIE DE SAALES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELEURL PHARMACIE DE SAALES

What is the revenue of SELEURL PHARMACIE DE SAALES ?

The revenue of SELEURL PHARMACIE DE SAALES in 2017 is 980 k€.

Is SELEURL PHARMACIE DE SAALES profitable?

Yes, SELEURL PHARMACIE DE SAALES generated a net profit of 33 k€ in 2023.

Where is the headquarters of SELEURL PHARMACIE DE SAALES ?

The headquarters of SELEURL PHARMACIE DE SAALES is located in SAALES (67420), in the department Bas-Rhin.

Where to find the tax return of SELEURL PHARMACIE DE SAALES ?

The tax return of SELEURL PHARMACIE DE SAALES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELEURL PHARMACIE DE SAALES operate?

SELEURL PHARMACIE DE SAALES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.